PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for Metformin:

Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.

This is a summary of the risk management plan (RMP) for Metformin. The RMP details important risks of Metformin, how these risks can be minimised, and how more information will be obtained about Metformin's risks and uncertainties (missing information). Metformin's summary of product characteristics (SmPC) gives essential information to healthcare professionals and patients on how Metformin should be used.

I. The medicine and what it's used for:

Metformin Prolonged release tablet contains the active ingredient metformin hydrochloride and belong to a group of medicines called biguanides, used in the treatment of diabetes.

Metformin is used for the treatment of Type 2 (also known as non-insulin dependent) diabetes mellitus in adults when diet and exercise changes alone have not been enough to control blood glucose (sugar). Insulin is a hormone that enables body tissues to take glucose from the blood and to use it for energy or for storage for future use. People with Type 2 diabetes do not make enough insulin in their pancreas or their body does not respond properly to the insulin it does make. This causes a build-up of glucose in the blood which can cause a number of serious long-term problems so it is important that you continue to take your medicine, even though you may not have any obvious symptoms. /…/ makes the body more sensitive to insulin and helps return to normal the way your body uses glucose.

DocuSign Envelope ID: 5DD09E05-FD47-46A2-AF69-A094CA7902B7

Metformin is associated with either a stable body weight or modest weight loss.

Metformin is specially made to release the drug slowly in your body and therefore are different to many other types of tablet containing metformin.

Adults can take Metformin on its own or together with other medicines to treat diabetes (medicines taken by mouth or insulin).

II. Risks associated with the medicine and activities to minimize or further characterize the risks:

Important risks of Metformin, together with measures to minimize such risks and the proposed studies for learning more about Metformin's risks, are outlined below.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the summary of product characteristics (SmPC) addressed to patients and healthcare professionals.
- Important advice on the medicine's packaging.
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without Prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

II.A. List of important risks and missing information

Important risks of Metformin are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely administered.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is enough proof of a link with the use of Metformin. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal

DocuSign Envelope ID: 5DD09E05-FD47-46A2-AF69-A094CA7902B7

product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 2: Summary of safety concerns

Important Identified Risks	• Lactic acidosis including: - Use in patients with renal dysfunction with GFR <45 ml/min - Concomitant use of iodinated contrast media.
Important Potential Risks	• None
Missing Information	• Use in pregnancy and lactation

II.B. Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C. Post authorisation Development Plan

II.C.1 Studies Which Are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of metformin.

II.C.2 Other Studies in Post Authorisation Development Plan

There are no studies required for Metformin.